Rappta Therapeutics

Rappta Therapeutics is a leading optimization-stage biopharmaceutical company. We are researching a series of first-class anticancer molecules that can reactivate the key tumor suppressor factor protein phosphatase 2A (PP2A). Rappta's proprietary tools and understanding of the target enable us to therapeutically reactivate PP2A, a key enzyme that regulates protein dephosphorylation and tumor growth.